IMU (ASX) Why IMU is a multi multi bagger

Originally posted by Gossy29: ↑

These abstracts are viewable now at this link :

https://cslide.ctimeetingtech.com/esmo2023/attendee/confcal_2/presentation

One for CheckVacc and one for HER-VAXX. To find them, you can go to the "All Posters" view and then use the search bar to find what you're after, ie. I searched CF33. Personally only really interested in the checkvacc one but I dont think there is anything new in it. I have pasted it below but it only includes patients from Dec 2022 and they are from the low dose cohorts.........see below :

487P - Induction of an inflammatory tumor microenvironment with oncolytic virus CF33-hNIS-antiPD-L1 intratumoral injection in patients with metastatic triple-negative breast cancer (mTNBC)
Presentation Number
487P
Speakers
Jamie Rand(Duarte, United States of America)
Onsite Poster display date
Saturday, 21 October 2023
Abstract
Background
CF33-hNIS-anti-PD-L1 (CHECKvacc) is a novel chimeric orthopoxvirus with robust anti-cancer activity in TNBC xenografts. CHECKvacc increased CD8+ T cell infiltration and favorably modulated the tumor microenvironment (TME) in xenograft models. Here we report data from the ongoing first-in-human clinical trial of CHECKvacc intratumoral (IT) injections in patients with mTNBC.
Methods
This is a phase I, single center, single arm trial of CHECKvacc IT. Eligibility criteria include patients with mTNBC that progressed on ≥ 2 chemotherapy regimens and have at least 1 tumor amenable to IT injections. Patients receive CHECKvacc IT at 1 of 8 assigned escalating dose levels on Days 1 and 15 of each 28-day cycle for 3 cycles. Primary objective is to evaluate safety and tolerability. Secondary objectives are to determine recommended phase II dose and efficacy. Exploratory objectives include assessment of TME immune modulation. Formalin fixed tissue biopsies were assessed by multiplex immunofluorescence for CD3, CD8, PD-L1, and pan-cytokeratin and digitally quantified for densities of immune phenotypes. PD-L1 expression was also assessed by a pathologist for a combined positive score (CPS).
Results
From October 2021 to December 2022, 8 patients were enrolled in this ongoing study and received ≥1 dose of CHECKvacc at 1 of the first 3 dose levels (1x105, 3x105, 1x106 PFU). There were no dose limiting toxicities. Six patients had evaluable baseline and post-treatment tissues for immune quantification. From baseline to cycle 1 day 2, CD8+ T cells in the TME increased in 5 of 6 patients (median increase: 34%; range: 9-251%). CD4+ T cells increased in 4 of 6 patients (median increase: 39%; range: 23-73%). PD-L1 expression by CPS increased in 5 of 6 patients (range of increase: 4-50%; p=0.063 by Wilcoxon signed-rank test).
Conclusions
CHECKvacc induces tumor infiltration of CD4+ and CD8+ T cells. Upregulation of PD-L1 within the TME further suggests immune activation by CHECKvacc. The clinical trial is ongoing to further assess dose escalation, tumor response, and the potential for future combination trials with systemic therapies, such as checkpoint blockade and chemotherapy.
Clinical trial identification
NCT05081492.
Legal entity responsible for the study
City of Hope Comprehensive Cancer Center.

Expand

Thanks for finding and sharing!
Shame limited info, though some new technical positive information is there.

No.	Vol.	Price($)
5	580359	5.6¢

No.

Vol.

Price($)

580359

5.6¢

Price($)	Vol.	No.
5.7¢	686331	5

Price($)

Vol.

No.

5.7¢

686331

No.	Vol.	Price($)
5	580359	0.056
15	1342805	0.055
9	734375	0.054
9	3805521	0.053
18	1535537	0.052

No.

Vol.

Price($)

580359

0.056

1342805

0.055

734375

0.054

3805521

0.053

1535537

0.052

Price($)	Vol.	No.
0.057	686331	5
0.058	1249150	9
0.059	191714	3
0.060	1632398	13
0.061	791000	5

Price($)

Vol.

No.

0.057

686331

0.058

1249150

0.059

191714

0.060

1632398

0.061

791000

(20min delay)
Last 5.6¢		Change 0.001(1.82%)		Mkt cap ! $411.5M

Open	High	Low	Value	Volume
5.5¢	5.7¢	5.3¢	$731.7K	13.32M

Thanks for finding and sharing!Shame limited info, though some...

Background

Methods

Results

Conclusions

Clinical trial identification

Legal entity responsible for the study

Talking Australia's very competitive property landscape: Realty Talks

Noronex joins forces with South32 to look for copper in Namibia

AI stocks: What to expect in 2024-25

Evolution shares up 3% on quarterly results for June showing rise in gold production

Andrew Forrest was seemingly possessed by the spirit of hydrogen – now he's cut 700 jobs and canned FFI

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Thanks for finding and sharing!Shame limited info, though some...

Background

Methods

Results

Conclusions

Clinical trial identification

Legal entity responsible for the study

Top Stories

Talking Australia's very competitive property landscape: Realty Talks

Noronex joins forces with South32 to look for copper in Namibia

AI stocks: What to expect in 2024-25

Evolution shares up 3% on quarterly results for June showing rise in gold production

Andrew Forrest was seemingly possessed by the spirit of hydrogen – now he's cut 700 jobs and canned FFI

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News